



LJMU Research Online

Banat, IM, Diaz De Rienzo, MA and Quinn, GA

Microbial biofilms: biosurfactants as antibiofilm agents.

<http://researchonline.ljmu.ac.uk/7241/>

Article

Citation (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

Banat, IM, Diaz De Rienzo, MA and Quinn, GA (2014) Microbial biofilms: biosurfactants as antibiofilm agents. Applied Microbiology and Biotechnology, 98 (24). pp. 9915-9929. ISSN 0175-7598

LJMU has developed [LJMU Research Online](#) for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact researchonline@ljmu.ac.uk

<http://researchonline.ljmu.ac.uk/>

Microbial biofilms: biosurfactants as antibiofilm agents

Ibrahim M Banat^{1*}, Mayri A. Díaz De Rienzo and Gerry A. Quinn³

¹ School of Biomedical Sciences, University of Ulster, Coleraine, BT52 1SA, Northern Ireland, UK.

² School of Chemical Engineering and Analytical Science, University of Manchester, Manchester, UK.

³ College of Medicine, Swansea University, Swansea, SA2 8PP, Wales, UK.

Key words: Biosurfactants, biofilm, disruption, antimicrobial, antibiofilm, dispersal agents, adjuvants.

* Corresponding author email: im.banat@ulster.ac.uk

Abstract

1
2 Current microbial inhibition strategies based on planktonic bacterial physiology have been
3
4 known to have limited efficacy on the growth of biofilms communities. This problem can be
5
6 exacerbated by the emergence of increasingly resistant clinical strains. All aspects of biofilm
7
8 measurement, monitoring, dispersal, control and inhibition are becoming issues of increasing
9
10 importance. Biosurfactants have merited renewed interest in both clinical and hygienic
11
12 sectors due to their potential to disperse microbial biofilms in addition to many other
13
14 advantages. The dispersal properties of biosurfactants have been shown to rival that of
15
16 conventional inhibitory agents against bacterial and yeasts biofilms. This makes them
17
18 suitable candidates for use in new generations of microbial dispersal agents and for use as
19
20 adjuvants for existing microbial suppression or eradication strategies. In this review we
21
22 explore aspects of biofilms characteristics and examine the contribution of biologically
23
24 derived surface-active agents (biosurfactants) to the disruption or inhibition of microbial
25
26
27
28
29 biofilms.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Introduction

1
2 Microorganisms in general gravitate towards solid surfaces forming biofilms as a strategy to
3 protect themselves from environmental challenges. Such deposition and subsequent biofilm
4 formation is a phenomenon that happens naturally and is usually part of the microorganisms'
5 strategy to protect themselves from external toxic factors (Pereira et al. 2007). They have
6 the ability to sense their own cell density, communicate and behave as a population through
7 cell to cell signalling, a phenomenon known as quorum-sensing (Liu et al. 2012). This
8 behaviour has been documented for some time in microbial biofilm formations (Davies 2003)
9 and is dependent on the nutritional/environment and the maturation stage of development of
10 the microorganisms. Microbial biofilms represent a distinct bacterial physiology characterised
11 by a multicellular phenotype that is fundamentally different from planktonic bacteria. They
12 have been implicated in chronic and recalcitrant healthcare associated infections (Dowd et
13 al. 2008), the dissemination of community acquired diseases (Stewart et al. 2012), effective
14 hygienic processing, increased failure rate of anti-infective therapy (Bueno, 2014) and
15 marine water and electronics environments (Lourenco et al. 2011). Biofilms that are
16 composed of one species are relatively rare in the majority of the natural environment; rather
17 microorganisms tend to be found in complex multispecies communities associated with
18 surfaces (Stoodley et al. 2002).

19
20 Until recently the differences between planktonic and biofilm physiologies seemed
21 inconsequential. Standard bacterial inhibition tests were almost exclusively based on
22 planktonic bacterial physiology and not the biofilm physiology even though these conditions
23 were not readily observed in the natural environment. The standard planktonic bacterial
24 physiology is typically exemplified by free-living single bacteria with optimal nutrition, gas
25 exchange and agitation (typically 250rpm) (Bueno 2014; Kotulova and Slobodnikova, 2010).

26
27 In contrast, the biofilm physiology has multicellular differentiation, multicellular
28 communication, internal architecture and rudimentary fluid transport systems (Girard et al.
29 2010; Leis et al. 2005). More importantly for in-vitro testing procedures, biofilms have
30 variable levels of nutrients, gas exchange, little or no agitation and therefore slower growth.

1 This difference in bacterial physiology can be critical especially in clinical situations where
2 there is a higher production of virulence factors in pathogens such as *Pseudomonas*
3 *aeruginosa* (Croda-García et al. 2011). In the biofilm physiology these pathogens can be one
4 to three orders of magnitude more resistant to dispersal/inhibition by conventional
5 chemotherapy than their planktonic counterparts of the same species (Girard et al. 2010;
6 Olson et al. 2002; Sepandj et al. 2004). This has been demonstrated in recent experiments
7 on biofilm formation during peritoneal dialysis, where all the antibiotics tested were effective
8 in laboratory MIC tests but (with the exception of gentamicin) lost their efficacy against
9 *Staphylococcus aureus* biofilms (Girard et al. 2010). Globally, methicillin resistant
10 *Staphylococcus aureus* (MRSA) is a serious problem due to limited efficacy of antibiotic
11 options, hospital hygiene and the resistance of biofilm associated clinical strains (Samadi et
12 al. 2012). Some biofilms also undergo phenotypic change as a result of chemotherapy
13 resulting in increased resistance.
14
15
16
17
18
19
20
21
22
23
24
25
26
27

28
29 New insights into biofilm physiology have now enabled researchers to design more
30 effective bacterial inhibition/dispersal strategies. There are two main inhibitory strategies,
31 based on the formulation of new antibiofilm compounds and the construction of biofilm
32 resistant surfaces (Villa and Cappitelli, 2013).
33
34
35
36
37

38 Some of the most promising candidates for the inhibition of bacterial biofilms have
39 come from biological surface-active agents (biosurfactants) (Kiran et al. 2010; Pradhan et al.
40 2013). Many of these have been reported to have anti-adhesive, antimicrobial and biofilm
41 disruption properties (Rodrigues et al., 2006a,b,c; Rodrigues et al., 2007). Enzymatically
42 synthesized surfactants such as lauryl glucose have also been reported to be effective
43 against fungal and bacterial biofilms (Dusane et al. 2010).
44
45
46
47
48
49
50

51 Biosurfactants are a heterogeneous group of amphiphilic compounds produced
52 mainly by microorganisms that accumulate at the interface between liquid phases and
53 therefore reduce surface and interfacial tension. They have been recognised for some time
54 in a diverse array of potential applications in a wide range of industries including agriculture,
55 food, cosmetic, pharmaceutical and petroleum industries (Banat et al. 2010). The surface
56
57
58
59
60
61
62
63
64
65

1 and interfacial tension reducing properties of surfactants provide excellent detergency,
2 emulsification, foaming and dispersing traits, making them some of the most versatile
3 products in chemical processes (Desai and Banat 1997). They are highly sought after
4 molecules due to their specificity, low toxicity, high biodegradability, widespread applicability
5 and effectiveness at extremes of pH and temperature (Muthusamy et al. 2008).
6
7
8
9

10
11 Several strands of research have demonstrated that under certain testing conditions
12 biosurfactants can be more effective than many traditional biofilm inhibition and or disruption
13 strategies (Epstein et al. 2011). There have been many reviews of biosurfactants and their
14 potential applications in environmental and biomedical related areas (Neu 1996; Banat et al.
15 2010; Banat et al. 2000). There has been however renewed interest in biosurfactants in
16 relation to healthcare associated infections (Krasowska 2010). In addition, the rapid pace of
17 advances in biofilm inhibition, control/disruption and the emergence of biofilms as potential
18 reservoirs for the dissemination of disease have necessitated a review of the current state of
19 the art on biofilms measurements and potentially effective biosurfactants against microbial
20 biofilms.
21
22
23
24
25
26
27
28
29
30
31

32
33 To our knowledge the area of biofilms and role of biosurfactants within is becoming
34 an increasingly important topic of research yet has not been the subject of a review article. In
35 this review therefore we examine biofilms characteristics, monitoring and quantification and
36 the main classes of current biosurfactants in use, their contribution to the dispersal or
37 inhibition of biofilms, their scope and efficiency, quantification of this dispersal/inhibition and
38 the sources and limitations of their uses.
39
40
41
42
43
44
45
46
47
48

49 **The nature and functions of biosurfactants**

50
51 Biosurfactants are amphiphilic compounds of biological origin containing a hydrophilic region
52 (polar or non-polar) and a hydrophobic region (lipid or fatty acid). The hydrophilic group is
53 the base of the International Union of Pure & Applied Chemistry nomenclature i.e. those
54 biosurfactants containing rhamnose are described as rhamnolipids; while those containing
55 sophorose are sophorolipids and those generally containing a carbohydrate moiety including
56
57
58
59
60
61
62
63
64
65

1 the previously mentioned two types are described as glycolipids. Other lipopeptide
2 biosurfactants contain a lipophilic hydrocarbon chain described as hydrophobic and a polar
3 or hydrophilic part which is usually composed of a string of amino acids.
4
5
6
7

8 *Function*

9
10 Biosurfactants have been identified in many biological processes as the components of
11 cellular metabolism, motion and defence. They are found in great abundance in bacteria, in
12 biofilms, as quorum sensing molecules, lubricants, promoting the uptake of poorly soluble
13 substrates, as immune modulators, virulence factors, secondary metabolites and
14 antimicrobial compounds (Fracchia et al. 2012). In a review by Neu (1996) it has also been
15 proposed that biosurfactants act as important molecules for interfacial processes,
16 conditioning the microbial cell surface, interfaces and surfaces with which the
17 microorganisms interact. These biosurfactants can be found in greater concentrations in the
18 layers of cells associated with movement and hydration although they can have an
19 intracellular location.
20
21
22
23
24
25
26
27
28
29
30
31

32
33 Biosurfactants' also have important roles in the dissolution and accessibility of oil
34 molecules especially for oil degrading microorganisms; adhesion to hydrocarbons as a result
35 of the emulsification of water-insoluble substrate compounds; the de-adhesion from
36 interfaces; facilitating the in gliding of bacteria through wetting interfaces. Such surface
37 active molecules can also have a role in enhancing the interaction between microorganisms
38 and all the natural organic hydrophobic compounds interfaces including plant and animal
39 derived polymeric compounds and microbial exopolysaccharides (Neu 1996). The role of
40 bacterial biosurfactants has been extensively studied in *Pseudomonas* where they are
41 known to promote colonisation and migration-dependent structural development (Pamp and
42 Tolker-Nielsen 2007).
43
44
45
46
47
48
49
50
51
52
53

54
55 Other roles for biosurfactants including biocidal activity have been reported. This is
56 mainly related to the effects of the lipidic moiety against eucaryotic cells. This has also been
57 reported to lead to toxicity, lysis, pyrogenicity, mitogenicity and immunogenicity among other
58
59
60
61
62
63
64
65

1 effects (Wicken and Knox 1980). Lysis of red blood cells has been used as a selection
2 criterion for microorganisms producing biosurfactants (Satpute et al. 2009). Finally human
3 derived biosurfactants have recently received increased attention because of their role in
4 immunity and defence (Gakhar et al. 2010).
5
6
7
8
9

10 *Measurements of biosurfactants physical properties*

11 There are many methods employed to test physico-chemical properties of biosurfactants.
12
13 These are very important for base line comparisons. The standard tests are based on the
14 physical properties of biosurfactants such as measurement of reduced surface tension.
15
16 Other tests measure the critical micelle concentration (CMC) which is the concentration of
17 surfactants above which micelle formation occurs. The CMC for example of sodium dodecyl
18 sulphate in water (with no other additives or salts) at 25°C and, atmospheric pressure, is
19 8x10⁻³mol/l. The emulsification index (E24 or EI24) is another method used to characterize
20 a biosurfactants' ability to form a stable emulsion with a hydrophobic phase. The hydrophilic
21 phase in this instance is usually water which, can be mixed with Kerosene and the
22 biosurfactant, shaken vigorously and allowed to stand for 24 hours. The percentage
23 emulsion of the water solution in kerosene is reported as the E24 or EI24 (Desai and Banat
24 1997). Other characterisation methods in use are the oscillating jets and the maximum
25 bubble pressures measured in the presence of the surface active compounds.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44 *Conditions for monitoring biofilm formation*

45 There is no standard laboratory method for quantifying biofilms though there are preferred
46 methods.. In the past, planktonic bacterial inhibition assays have had to have strictly defined
47 experimental criteria in order to reduce variation in results and increase confidence in
48 antibiotic comparisons. However, these tests do not adequately represent different bacterial
49 growth physiologies such as that in biofilms. The first biofilm tests were very similar to these
50 planktonic experiments and created the impression that biosurfactants were weak
51 counterparts of conventional inhibitory agents. Later, research into biofilm inhibition showed
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 that these tests did not give an accurate reflection of the efficacy of biosurfactants. Today's
2 biosurfactant tests are more accurate and try to represent the in-situ environment as much
3 as possible. Many of these tests are based on pre-coating a surface with a known amount of
4 biosurfactant overlaid with microbial biofilm (O'Toole 2011). This can be alternated with
5 overlaying pre-existing biofilms with the test substance.
6
7
8
9

10
11 Since the biofilm physiology is distinct from the planktonic physiology, biofilm
12 experimental conditions have had to be adjusted accordingly. In terms of temperature the
13 biofilm cultivation is carried out at the optimal temperature for biofilm growth of a particular
14 species which may not be the same as the optimal temperature for planktonic growth, this
15 could mean that biofilm cultivation may be at 20 °C (even for clinical specimens) whilst others
16 may be at 10 °C in the cases of some environmental biofilms (Quinn et al. 2012).
17
18
19
20
21
22
23

24 In terms of nutrition, it is common practice for biofilms to be cultivated in a dilution of the
25 media that is used for planktonic cultivation, this is usually ½ to 1/5th of standard
26 concentrations reflecting the sub-optimal conditions of biofilm growth, however this practice
27 is not universally applicable (Stepanovic et al. 2004).
28
29
30
31
32

33 Since biofilms also grow slower than optimised planktonic conditions, the typical cultivation
34 period for biofilms can vary from 4 hours to 3-4 days or even 7-10 days in the case of slower
35 growing environmental biofilms (Quinn et al. 2012; Stepanovic et al. 2007). Agitation
36 considerations are equally important. In the earliest biofilm growth assays it was thought that
37 environments of high shear stress were necessary. However more recent research has
38 shown that environments of high agitation are not necessary for all biofilm growth and these
39 growth conditions can be considered strain specific. Rather biofilm tests are typically
40 conducted in almost static environments or environments of minimum perturbation (O'Toole
41 2011; Stepanovic et al. 2007).
42
43
44
45
46
47
48
49
50
51
52

53 The standard inoculation density of microorganisms also differs greatly from standard
54 planktonic tests. For planktonic MIC tests organisms are seeded at a density of 1×10^6 /ml of
55 fresh cells taken from the logarithmic stage of growth. In biofilm cultivation seeding densities
56 are typically a 1/100 dilution of a stationary phase culture (McLaughlin and Hoogewerf 2006;
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Quinn et al. 2012). Some researchers use biofilm induction agents such as high glucose or alcohol to aid biofilm formation but these may add unknown variables to the assay making the final biofilm data difficult to interpret.

Recently, Lourenco and co-workers (2014) published the results of an initiative to establish “minimum information about a biofilm experiments” (MIABiE) which is a project partly funded by EU grants to find a scientifically adequate procedures to document biofilm-related data. They asserted that this could be achieved through ensuring a set of minimum information that should be reported to guarantee the independent verification and interpretation of experimental results in a way that would allow their integration with biofilm related information generated by other fields.

Surfaces for the quantification of biofilm growth

The physiochemical properties of substrates used for biosurfactant evaluations can affect the nature of biofilm adhesion, the subsequent biofilm architecture in the case of monocultures or the selection of the microbial species which colonise in the case of mixed and environmental biofilms. Biofilms also express different repertoires of proteins or adhesion characteristics depending on the surface characteristics of the substrate they are attached to (Stoodley et al. 2002). Hence the choice of surface for biofilm cultivation is very important and must be taken into account even when comparing the results of inhibitory tests. .

The different surfaces used in biofilm tests range from animate/inanimate, rough/smooth, hydrophobic/ hydrophilic and liquid/air/liquid etc. Laboratory cultivation of biofilms can be conducted on many surfaces including glass, plastic, metal, silicone and tissue models (O'Toole 2011). In more comprehensive assessments of the inhibition potential biosurfactants can be applied to a broad range of surfaces especially in clinical environments. Research into the efficacy of Pseudofactin II (a newly characterised biosurfactant) used many different surfaces such as glass, polystyrene and silicone to cultivate biofilms in combination with different bacterial strains in order to demonstrate its

1 wide efficacy (Janek et al. 2010 & 2012). In other research on biofilms of *Salmonella*,
2 investigators used PVC and silicone (urethral catheters) as biofilm substrates to demonstrate
3 the applicability of biosurfactants in the reduction of biofilm formation/attachment (Mireles et
4 al. 2001).
5
6
7
8
9

10 **Quantification of biofilm inhibition/dispersal**

11 *The Calgary Biofilm Device*

12
13 One of the first devices employed to measure biofilm inhibition/dispersal was the Calgary
14 biofilm device (CBD) (Olson et al. 2002). This technique is widely used in flow tests for
15 microbial biofilms (Rivardo et al. 2009; Girard et al. 2010; Rivardo et al. 2011). The
16 cultivation chamber consists of a 96-well plate together with a lid that contains 96 peg
17 projections (Figure 1). These pegs provide a maximum surface area for the growth of
18 biofilms. The CBD has a typical seeding density of 1×10^4 to 1×10^6 bacteria per well or
19 McFarland standard 1, a cultivation speed of ≥ 10 rpm and an incubation period of 4-24 h
20 depending on species and conditions (Girard et al. 2010).
21
22
23
24
25
26
27
28
29
30
31
32

33 Microbial biofilms are cultivated on test pegs projecting into a growth media, removed
34 after a given time, washed and then inserted into wells containing an inhibitory/test
35 substance. Mature biofilms can be subsequently detached from the pegs by ultrasonic
36 treatment. The detached microbes can be enumerated by standard cultivation techniques or
37 quantified by measuring their optical density at 650nm. The amount of bacterial inhibition of
38 the biofilms is referred to as the minimal biofilm eradication concentration (MBEC). The
39 MBEC represents the lowest dilution of inhibitory substance. If cultivation conditions require
40 a greater circulation of media the lid of this plate can be modified to accommodate 12 media
41 channels into which the 96 pins are extended.. In this manner 96 pins can be simultaneously
42 exposed to a given culture (Ceri et al 1999)
43
44
45
46
47
48
49
50
51
52
53
54

55 Although the CBD was a welcome departure from planktonic based testing regimes
56 and a step towards a more accurate portrayal of biofilm physiology; the method still relied on
57 the final detection of viable planktonic microorganisms rather than directly measuring the
58
59
60
61
62
63
64
65

1 whole biofilm biomass. It also assumes that bacteria from viable biofilms can immediately
2 rejuvenate on agar or directly into culture broth. This is an important point in biofilm
3 physiology since studies on the resuscitation of bacterial cells have shown that some
4 microorganisms may still be viable in the biofilm but not immediately cultivatable especially
5 after prolonged chemotherapy (Rollet et al. 2009). This is also important when considering
6 the negative impacts of the selective pressure of chemotherapy on biofilm forming
7 pathogens. In some cases it has been shown that severe chemotherapy can induce a viable
8 but dormant pathogen that can resuscitate in more favourable conditions to contribute to the
9 chronic character of a biofilm infection (Zhang 2014).

10
11 Finally, the CBD measures the amount of cells in a biofilm and not the biofilm
12 biomass i.e. the biofilm + extra polymeric substances (EPS). However biofilm substances
13 that are not cells can constitute a significant proportion of biofilms (Decho 2013).
14
15
16
17
18
19

20 *Biofilm growth within flow-through devices*

21
22 Biofilms can be analysed under flow conditions by a variety of methods including the CBD.
23
24 However another flow system currently used to test biofilms is the BioFlux 200 system
25 (Fluxion Biosciences Inc., South San Francisco, CA) (Benoit et al. 2010; Ding et al 2014;
26 Chabane et al. 2014). One of the benefits of such a system is that it is amenable to real-time
27 analysis of the biofilm through automated image acquisition within specialized multi-well
28 plates. In order to cultivate biofilms, microfluidic channels are primed with the culture
29 medium at a specific rate. Each channel is seeded with an overnight culture with a cell
30 density of 10^7 CFU. The biofilms are subsequently incubated at specific time and
31 temperature levels in order for the bacterial cells to adhere. Once the biofilms have formed,
32 planktonic cells are removed, and washed. The biofilm growth can then be recorded using a
33 phase contrast or fluorescence microscope (Ding et al. 2014).
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

58 *In-vitro Biofilm formation in a 8 well chamber*

59
60
61
62
63
64
65

1 Another variation of biofilm chamber growth is the use of an 8-well chamber slide. This
2 method uses 200µL aliquots of mid-logarithmic cells diluted in fresh medium (1:2500 (v/v)).
3
4 The medium can be replaced every 12h if the biofilm takes longer than 24h to grow or as
5
6 needed to maintain bacterial viability (O'Toole 2011).
7

8
9 The resulting biofilms can be visualized by aspirating the medium and washing with
10 saline. The viability of the biofilm cells is typically assessed by the addition of BacLight
11 Live/Dead stain (O'Toole 2011). Additionally, EPS or pili in the biofilms can be visualized
12
13 under SEM by dehydrating the sample in a graded series of alcohols and adding
14
15 hexamethyldisilazane (HMDS) (Araujo et al 2003).
16
17
18
19
20
21

22 **Crystal violet quantification of biofilm growth**

23
24 One of the most commonly used methods to assess the effectiveness of biosurfactants and
25 biofilm inhibitory agents is the crystal violet quantification of biofilm growth (O'Toole 2011).
26
27 The technique involves the cultivation of a microbial biofilm in a 96-well (high bind PVC)
28 plate, a rinsing step and final staining with 1% crystal violet. Biofilms are quantified by
29
30 assessing the proportion of crystal violet bound to the biofilm biomass in control and test
31
32 cultivations. The surfaces of high-bind 96 well plates were originally designed for ELISA
33 tests and hence contain organically compatible high protein binding plastic (other types of
34
35 PVC have different binding properties). This type of surface allows the binding of large
36
37 molecules with ionic groups or large hydrophobic regions and permits a wide diversity of
38
39 bacteria to form biofilms.
40
41
42
43
44
45

46
47 The advantages of this method of biofilm quantification is that dispersal/inhibition can
48 be measured directly in-situ rather than extrapolated from viable planktonic microorganisms.
49
50 The crystal violet stains the total biofilm biomass which includes EPS and extracellular
51 proteins rather than just its component cells. There may be some variability in the results
52
53 obtained from this test but this can be rectified by a higher number of replicates which is
54
55 afforded by the 96-well plate.
56
57
58
59
60
61
62
63
64
65

Quantification of biofilm inhibition by direct analysis

1
2 One of the simplest methods of biofilm quantification is by direct measurements of bacterial
3 viability as directly proportional to biofilm dispersal (Rodrigues et al. 2004). This technique
4 does not measure total biofilm biomass or biofilm adhesion, however it is a useful validation
5 step for other methods. This quantification becomes more problematic for mixed bacterial
6 populations and viable but non-cultivable microorganisms.
7
8
9

Bacterial Viability Quantification

10
11
12
13
14
15
16
17 There are several viability dyes that are used to quantify biofilm. Most of these are based on
18 DNA binding. These include two of the most widespread fluorescent dyes, propidium iodide
19 which binds to DNA when the cell nuclear membrane is damaged fluorescing red and syto 9
20 green which binds to DNA when the nuclear membrane is intact (Lehtinen et al. 2004). In the
21 case of biofilms this quantification can be complicated by extracellular DNA but this might
22 only apply in very dense biofilms.
23
24
25
26
27
28
29
30

Digital quantification

31
32
33
34
35 Fluorescent stains are easily quantified by digital technologies. This makes it easier to
36 assess biofilm growth/dispersal. As mentioned above although this technique may be
37 directly quantitative for bacterial monolayers or biofilms of several layers thick, there are still
38 technical issues however with proportional measurements of complex multi-layered biofilms
39 with all the associated dead spaces and channels.
40
41
42
43
44
45
46
47

Other microscopic quantification

48
49
50
51 Scanning electron microscopy (SEM) has proved to be a useful technique for pictorial
52 representations of biofilms, however the preparation methods involved including successive
53 dehydrations in alcohol and gold sputtering can fundamentally alter the composition and
54 biofilm architecture of biofilms. More promising results have recently been obtained by the
55 use of cryo-SEM (Alhede et al. 2012). As previously stated, the biofilm substrates used in
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

microscopic techniques have to be quite robust such as glass; however this may also have a role in determining the formation of the biofilm and cannot always be used in direct comparisons to the same biofilms growth on plastic or silicone.

Biosurfactants as antibiofilm molecules

One of the most common questions posed on the effects of biosurfactants on biofilms is why are there still biofilms when biosurfactants are powerful molecules mostly leading to biofilm inhibition? The current hypothesis is that surface active molecules play a major role in the development and maintenance of biofilms partly through the maintenance of water channels through the biofilm which enhances nutrients movements and gaseous exchange, and which ultimately leads to the dissociation of parts of the biofilm into planktonic mobile forms (Marchant and Banat 2012). However the current focus of research is the ability of biosurfactants to disrupt established biofilms and prevention of the development of new ones. Although there are diverse arrays of biosurfactants, this review focuses on those in current use or known for the ability to disrupt biofilms in-vitro (Table 1).

Lipopeptides biosurfactant as disruptor molecules

Lipopeptides are one of the largest groups of biosurfactants that can effectively disperse microbial biofilms. These generally referred to by their group name although they can be composed of three or more varieties of homologous or congeners molecules. This group includes surfactins, polymixins, fengycins and fusaricidins (Krupovic et al. 2007; Pecci et al. 2010; Raza et al. 2009; Rivardo et al. 2009). Structurally lipopeptides are composed of a hydrophilic peptide attached to hydrophobic lipid or fatty acid. The peptides can either be aliphatic, branched or cyclic. Similarly, the lipids chains can vary in length and conformations ensuring a wide diversity of structures. Many of the current lipopeptides reported to inhibit/disperse biofilms originate from *Bacillus* or *Paenibacillus* (Kim et al. 2009; Price et al. 2007; Quinn et al. 2012).

Polymyxins

1
2 Polymyxins, are a class of non-ribosomally synthesized cyclic lipopeptides. They are
3
4 generally produced as secondary metabolites of *Bacillus* or similar species (Price et al.
5
6 2007). Their typical structure is that of a cyclic polypeptide attached to a fatty acid tail. They
7
8 can also contain exotic bacterial amino acids such as 2, 4, diaminobutyric acid (DAB) (Figure
9
10 2A). Polymyxins are known have a limited clinical spectrum of inhibition in the treatment of
11
12 Gram negative infections. There are several commercially available formulations of
13
14 polymyxins including Colistin (polymyxin E) (Falagas and Kasiakou 2005), Neosporin and
15
16 Polymyxin B which can be supplied as polymyxin B sulphate (a mixture of polymixins) (He et
17
18 al. 2010). Polymyxin can also be combined with trimethoprim for eye conditions (Polytrim)
19
20 and with neomycin and bacitracin to make triple antibiotic ointment Neosporin.
21
22
23

24
25 Polymyxins are the last drug of choice in some infections and are often prescribed
26
27 with caution due to fears of their toxicity however this estimation has been reappraised in the
28
29 light of more rigorous testing (Arnold et al. 2007). Polymyxins are prescribed intestinally or
30
31 topically as cream or powders in most cases of multi drug resistant *Acinetobacter baumannii*,
32
33 *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa* (Falagas and Kasiakou 2006; Milletti
34
35 Sezgin et al. 2012). Polymyxin has been reported to reduce biofilms of *Pseudomonas*
36
37 *aeruginosa* at concentrations of 20µg/ml by 99% in a 12 hour time period and almost
38
39 completely over 24 hours (Jass and Lappin-Scott 1996). However these results are based
40
41 on the viability of bacteria and not their dispersal; although it was noted that bacterial cells
42
43 displayed an altered morphology. Polymyxin E (colistin) is recommended as an early
44
45 aggressive therapy to delay the onset of chronic *P. aeruginosa* infection (which frequently
46
47 forms biofilms) or intermittent colonization in cystic fibrosis patients, a combination of oral
48
49 ciprofloxacin with colistin inhalation (Doring et al. 2000).
50
51
52

53
54 Polymyxin D1 has been shown to be effective against mixed bacterial biofilms,
55
56 however our earlier work has shown this compound was found in combination with
57
58 fusaricidin and surfactin in undefined ratio's (Quinn et al. 2012). This complex of
59
60 biosurfactants was also reported to inhibit the formation of biofilms of both Gram positive
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

bacteria such as *Staphylococcus aureus*, *Streptococcus bovis*, *Bacillus subtilis* and *Micrococcus luteus* and Gram negative bacteria such as *Pseudomonas aeruginosa*. Most interestingly the biosurfactants were able to inhibit the formation of mixed species biofilms such as self-assembling marine biofilm (SAMB) in co-incubation assays by 99.3% and disrupt previously established mixed SAMB by 72.4% (Quinn et al. 2012).

The mechanism of action of polymyxins on bacterial biofilms remains largely undefined. However the mechanism of action on planktonic bacteria is proposed to be related to their high affinity for lipopolysaccharide (LPS) (Domingues et al. 2012). This induces LPS aggregation increasing the surface charge of LPS leading to internalization and binding to the bacterial phosphatidylglycerol-rich membrane leaflets which in turn induces leakage of cellular contents (Domingues et al. 2012).

Fengycin-like lipopeptides

Fengycin-like lipopeptides are derived from *Bacillus subtilis* and *Bacillus licheniformis*. These are cyclic lipopeptides containing 8-10 amino acids linked to a beta hydroxy fatty acid (Figure 2B). Fengycin-like peptides have also been reported to be involved in the inhibition of biofilms (Xu et al. 2013) causing up to 90% dispersion of Gram positive *S. aureus* biofilms and up to 97% dispersion of Gram negative *E. coli* biofilm (Rivardo et al. 2009) .

Putisolvin

Putisolvin is a cyclic lipodepsipeptide isolated from *Pseudomonas putida*. This has been characterised in two forms, putisolvin I and putisolvin II. This biosurfactant has a four member cyclic peptide; the valine residue in putisolvin I being substituted by a leucine or isoleucine in putisolvin II. (Figure 2C) (Dubern et al. 2006). Although Putisolvin is involved in biofilm formation by *Pseudomonas putida* these surfactants have also been shown to be effective dispersal agents in pre- and post-addition to biofilms of other *Pseudomonas* sp. strains (Kuiper et al. 2004).

Pseudofactin

1
2 Pseudofactin is a cyclic lipodepsipeptide derived from *P. fluorescens*. The structure of
3
4 Pseudofactin is based on that of a palmitic acid attached to the terminal amino group of an
5
6 eight amino acid peptide chain. The C-terminal carboxylic group of the last amino acid forms
7
8 a lactone with the hydroxyl of third amino acid which is a threonine (Figure 2D). Pseudofactin
9
10
11 It has been reported to be 36-90% effective against the adhesion of five species of bacterial
12
13 biofilms on glass, polystyrene and silicone substrates. These strains include *Enterococcus*
14
15 *faecalis*, *Escherichia coli*, *Staphylococcus epidermidis*, *Enterococcus hirae* and *Proteus*
16
17 *mirabilis*. Similar inhibition of adhesion (92-99%) was reported on yeast biofilms of *Candida*
18
19 *albicans* at concentrations of 0.5 mg/ml (Janek et al. 2012).
20
21

22 Pseudofactin has been documented to produce an effective dispersal of 26-70% on
23
24 pre-existing biofilms grown on untreated surfaces and has been shown to cause a marked
25
26 inhibition of the initial adhesion of *E. hirae*, *E. coli*, *E. faecalis* and *C. albicans* to silicone
27
28 urethral catheters. Total growth inhibition of *S. epidermidis* has been observed at the
29
30 highest concentration tested (0.5 mg/ml), which causes a partial (18-37%) inhibition of other
31
32 bacteria, a 8-9% inhibition of *C. albicans* yeast growth and a 99% prevention of adhesion
33
34 (Janek et al. 2012).
35
36
37
38
39

Surfactin

40
41
42 Surfactins are one of the most powerful biosurfactants originally isolated from *Bacillus*
43
44 *subtilis* and consist of a cyclic peptide heptamer connected to a 13-15 carbon, beta-hydroxy
45
46 fatty acid chain (Figure 3A). Unfortunately surfactins can also be indiscriminately cytotoxic
47
48 with haemolytic activities due to its interactions with cellular membranes (D'Auria et al.
49
50 2013). They have been reported to inhibit the growth of biofilms of *Salmonella* sp. cultivated
51
52 on PVC microtitre wells and urethral catheters (Mireles et al. 2001). They have been
53
54 observed to cause a rippling effect in lipid bilayers perhaps indicating a clue to the
55
56 mechanism of biosurfactant action or biofilm permeability or integrity (Brasseur et al. 2007)
57
58
59
60
61
62
63
64
65

1 most likely through the formation of some kind of channels within the biofilm increasing
2 penetrability.
3
4
5

6 *Complexes of lipopeptides*

7
8 Although many lipopeptides have been characterised for experimental purposes as pure
9 compounds they are in fact usually associated with groups of similar compounds. This is
10 reflected in their availability as minimally purified preparations. Siram and co-workers (2011)
11 reported on one such complex of lipopeptide biosurfactants produced by a heavy metal
12 tolerant strain of *Bacillus cereus*. This surfactant effectively dispersed biofilms at an active
13 dose of 0.150µg and was noted to be very tolerant of fluxes in pH, temperature and NaCl, in
14 addition to being resistant to high levels of iron, lead and zinc whilst maintaining
15 antimicrobial and biofilm dispersal activity. Another complex of surfactants isolated from
16 *Paenibacillus polymyxa*. PPE was found to consist of polymyxin D1, fusaricidin B and traces
17 of surfactin (Deng et al. 2011; Quinn et al. 2012) (Figure 3 B & C).
18
19
20
21
22
23
24
25
26
27
28
29
30

31 A preparation containing 2mg/ml of such lipopeptides tested in one of our
32 laboratories inhibited (87-98%) the formation of many Gram positive bacterial biofilms such
33 as *Staphylococcus aureus*, *Streptococcus bovis*, *Micrococcus luteus*, *Bacillus subtilis* and
34 also some Gram negative bacteria such as *Pseudomonas aeruginosa* (Quinn et al. 2012).
35 More uniquely in terms of biofilm experiments, this combination of lipopeptides was effective
36 against mixed environmental strains' biofilms formation (99% inhibition) and up to 74% in
37 pre-established biofilms.
38
39
40
41
42
43
44
45
46
47
48

49 *Synergy of lipopeptides with other inhibitors*

50
51 Lipopeptide biosurfactants have been combined with conventional antibiotics in an effort to
52 produce synergistic inhibition effects. Lipopeptides isolated from *Bacillus licheniformis*
53 (strain V9T14) were reported by Rivardo and co-workers (2011) to have a synergistic effect
54 against a mature 24-h uropathogenic *E. coli* (CFT073) biofilms when combined with
55 ciprofloxacin, cefazolin, piperacillin, ceftriaxone, ampicillin, tobramycin and
56
57
58
59
60
61
62
63
64
65

1 trimethoprim/sulfamethoxazole. They concluded that some combinations led to total
2 eradication of biofilm; however the antibiotics on their own had poor inhibitory activity
3
4 (Rivardo et al 2011).
5
6
7

8 *Glycolipid biosurfactants as antibiofilm molecules* 9

10 Glycolipids consist of a carbohydrate attached to aliphatic or hydroxy-aliphatic acid. These
11 are one of the most studied groups of biosurfactants in other fields although they are
12 underrepresented as agents of biofilm dispersal.
13
14
15
16
17

18 *Rhamnolipids* 19

20 Rhamnolipids consist of di- or mono-rhamnose sugars attached to a fatty acid chain (Figure
21 3 D & E). Originally isolated from *Pseudomonas aeruginosa*, analogues are also produced
22 by isolates of *Burkholderia* (Costa et al. 2011), *Renibacterium salmoninarum*, *Cellulomonas*
23 *cellulans*, *Nocardioides* and *Tetragenococcus koreensis* (Abdel-Mawgoud et al. 2010).
24 Rhamnolipids have been reported as a potential replacement to chemical surfactants for
25 many uses in the oil and petroleum industries and in use for the bioremediation of oil
26 contaminated environments (Marchant and Banat 2012a & b). They are frequently cited as
27 inhibitors of bacterial growth although their capacity to inhibit biofilms however has not been
28 as extensively documented.
29
30
31
32
33
34
35
36
37
38
39
40
41

42 Rhamnolipids are involved in biofilm formation in *Pseudomonads* sp. through the
43 promotion of motility, the inhibition of attachment and degradation of the matrix maintaining
44 channels throughout the biofilm for movement of water and oxygen (Boles et al. 2005; Davey
45 et al. 2003). These biosurfactants were previously reported as antibacterial against
46 *Staphylococcus aureus*, *Mycobacterium* sp, *Bacillus* sp, *Serratia marsecens*, *Enterobacter*
47 *aerogenes*, *Klebsiella pneumonia* and against fungi such as *Chaetomium globosum*,
48 *Aureobacidium pullulans*, *Gliocladium virens*, *Botryhs cinerea* and *Rhizoclonia solanii*
49 (Benincasa et al. 2004; Haba et al. 2003).
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Rhamnolipids have also been shown to be effective against biofilms of *Bordetella bronchiseptica* (Irie et al. 2005). The mechanism of biofilm inhibition is thought to be by the detachment of cells; however some unattached cells may still be viable. They have been reported to disrupt pre-formed biofilms such as *Bacillus pumilus* from the marine environment (on polystyrene microplates) resulting in a dispersal at sub-MIC concentrations and confirming ability to remove pre-formed biofilms (Dusane et al. 2010). This was corroborated by scanning electron microscopy which showed that rhamnolipids removed biofilm-matrix components (Dusane et al. 2010). The effects of rhamnolipids on pre-formed biofilms of *P. aeruginosa* PAO1 generated in our laboratory can be seen here in Figure 4.

Rhamnolipids were also been tested on devices such as voice prostheses and have been noted to reduce the initial deposition rates of biofilm after 4h (Rodrigues et al. 2006a). A maximum reduction of adhesion ($\approx 66\%$) was observed when the surfaces such as silicone rubber had been preconditioned with rhamnolipids using biofilms of *Streptococcus salivarius* and *Candida tropicalis*. The number of cells adhering after 4h was reduced to $\approx 48\%$ for *Staphylococcus epidermidis*, *Streptococcus salivarius*, *Staphylococcus aureus* and *C. tropicalis* in comparison to controls. This group managed to optimise the actions of this biosurfactant on the detachment of microorganisms adhering to silicone rubber by perfusing the flow chamber with a biosurfactant containing solution followed by passage at the liquid-air interface. By this method they were able to achieve a high detachment (96%) for most of the microbial cells.

Rhamnolipids have also been shown to be effective dispersal agents for fungi disrupting pre-formed biofilms of *Yarrowia lipolytica* on glass surfaces by $\approx 67\%$ which was more effective in comparison to the surfactants cetyl-trimethyl ammonium bromide (CTAB) and sodium dodecyl sulphate (SDS) (Dusane et al. 2012).

It is important to note that although rhamnolipids can effectively disrupt biofilm formation and integrity which we observed through phase contrast microscopy where thick dense cellular biofilm (Figure 4A) of microcolonies structures on glass coverslips stained with crystal violet was much reduced in after treatment with rhamnolipids biosurfactants

1 (Figure 4B). These molecules are also known to be extracellular virulence factors and
2 related to the pathogenesis (infection procedure) in *Pseudomonas aeruginosa*. It has been
3 noted that rhamnolipids are also linked to increased lung epithelial permeability, rapid
4 necrotic killing of polymorphonuclear leukocytes and the malfunction of normal tracheal
5 ciliary motion in the respiratory system of infected patients (Read et al. 1992).
6
7
8
9

10 11 12 *Sophorolipids*

13 Sophorose lipids are typical glycolipids biosurfactants consisting of a dimer of sophorose
14 sugar and a long-chain fatty acid that are produced by yeasts belonging to the genus
15 *Candida*.
16
17
18
19
20

21
22 The synergy between sophorolipids and antibiotics has been studied as potential
23 strategy to disrupt biofilms using The LIVE/DEAD BacLight Bacterial Viability Kits as a
24 method for detection . This method employs two nucleic acid stains — the green-fluorescent
25 SYTO 9® stain and the red-fluorescent propidium iodide stain. These stains differ in their
26 ability to penetrate healthy bacterial cells. When used alone, SYTO 9 stain labels both live
27 and dead bacteria. In contrast, propidium iodide penetrates only bacteria with damaged
28 membranes, reducing SYTO 9 fluorescence when both dyes are present. Thus, live bacteria
29 with intact membranes fluoresce green, while dead bacteria with damaged membranes
30 fluoresce red. Joshi-Navare and Prabhune (2013) reported the the effect of sophorolipds in
31 the disruption of biofilms from *Escherichia coli*. Figure 5 illustrated the examination of cells
32 of *Bacillus subtilis* attached to coverslips after 48h and stained with LIVE/DEAD BacLight
33 showing the presence of individual bacteria, small clusters of cells (microcolonies), and
34 extended areas of the glass surface covered with large numbers of microcolonies of active
35 cells (Figure 5A), as well as, those which their membrane was damage due to the effect of
36 sophorolipids 5% (v/v) concentration after 30min of treatment (Figure 5B).
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

58 *Other Glycolipids as antibiofilm molecules*

59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Dusane et al. (2012) reported a glycolipid based on glucose and palmitic acid produced by a tropical marine *Serratia marcescens* was effective in inhibiting biofilms of the marine biofouling bacterium *Bacillus pumilus* and the adhesion of *C. albicans* and *P. aeruginosa* PAO1. This effect was also observed with preformed biofilms of these cultures on microtitre plate tests. Other complexes of glycolipids from *Brevibacterium casei* MSA19 have been reported to disrupt and significantly inhibit individual and mixed culture biofilms of human and fish at concentrations of 30 mg/ml (Kiran et al. 2010).

Antibiofilm glycolipids have also been isolated from *Lactobacillus* (Tahmourespour et al. 2011; Zakaria Gomaa 2013). In this case *L. paracasei* A20 produced biosurfactants that inhibit Gram-positive and Gram-negative bacteria, yeasts and filamentous fungi (Gudina et al. 2010). The biosurfactant also showed anti-adhesive activity against pathogenic *Candida albicans*, *Escherichia coli*, *Staphylococcus aureus*, *Staphylococcus epidermidis* and *Streptococcus agalactiae*. Glycolipids derived from plants have also been reported to inhibit biofilms. These include a novel hydroxyproline rich glycopeptide from the pericarp of *Datura stramonium* known as datucin which is also reported to eradicate biofilms of antifungal resistant *Candida albicans* (Mandal 2012).

Complex surfactant mixtures

Biosurfactants are seldom found in pure form or isolation and are often associated together with isomers or congeners that share similar physiochemical characteristics which makes the process of purification either exhaustive or uneconomical. However these complexes of biosurfactants may have the advantage of a broader applicability than pure compounds. The same is true of complexes of compounds in other environments; this can be illustrated by the large diversity of antimicrobial peptides and surfactants found on the skin of amphibians (Bevins and Zasloff 1990). Similarly in innate human defence, antimicrobial peptides such as human beta defensins 1 , 2 and 3 and related human neutrophil peptides (Ganz et al. 1985) are found in homogenous groups. .

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Combinations of biosurfactants have also been extracted from *Robinia pseudoacacia* and *Nerium oleander*. These secretions inhibited attachment of biofilms of *Candida albicans* on silicon and denture prosthesis at concentrations of 78µg/ml and 156µg/ml (Cochis et al. 2012). Other biosurfactants obtained from probiotic bacteria *Lactococcus lactis* 53 and *Streptococcus thermophilus* greatly reduced microbial numbers on preconditioned voice prostheses in an artificial throat model and induced a decrease in the airflow resistance that occurs on voice prostheses after biofilm formation (Gakhar et al. 2010).

Biosurfactants from fungi

Biosurfactants that inhibit biofilms have been found in fungi such as *Candida bombicola*. This produces sophorolipids that inhibit biofilms of *V. cholerae* (Mukherji and Prabhune 2014). Other strains of yeast such as *Candida sphaerica* have also been reported to produce biosurfactants such as lunasan (Luna et al. 2011). This inhibits the adhesion of *Pseudomonas aeruginosa*, *Streptococcus agalactiae* and *Streptococcus sanguis* to levels between 80-92%. Similarly rufisan from *Candida lipolytica* inhibits biofilm formation at concentrations greater or equal to 0.75 µg/ml against *S. aureus*, *Streptococcus agalactae*, *S. mutans* NS (Rufino et al. 2011).

Mammalian surface active secretions

From a chemotherapeutical perspective, the most interesting groups of biosurfactants are those produced by humans. Not much is known about these molecules however it has recently been reported that PLUNC ("Palate, lung, nasal epithelium clone") protein has anti-biofilm activity (Gakhar et al. 2010). These molecules are mainly produced as a secretory product of epithelia lining the airways tubes within mammals including humans. They are evolutionarily related to the lipid transfer/lipopolysaccharide binding protein (LT/LBP) family. PLUNC are believed to have novel biologically relevant surface active properties as they significantly reduce surface tension at the air-liquid interface within aqueous solutions they

1
2 also inhibited biofilm formation in the airways colonising potential pathogen *Pseudomonas*
3 *aeruginosa in vitro* at physiologically relevant concentrations (Gakhar et al. 2010).
4
5

6 **Conclusions**

7
8
9

10 It has been acknowledged that microbial biofilms lie at the heart of many recalcitrant patient
11 infections in the clinical environment, the dissemination of airborne pathogens and the
12 fouling of industrial surfaces. These problems are increasingly exacerbated by the rise of
13 resistant biofilm populations and the paucity of alternative eradication solutions.
14
15 Biosurfactants represent an emerging therapy which has inherent anti-bacterial, fungal and
16 viral properties with an ability to effectively disperse or disrupt such biofilms. Their use
17 therefore either on their own or as adjuvants to other antimicrobial chemotherapies may
18 represent a potential way forward in tackling biofilms in the future.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

References

- 1
2 Abdel-Mawgoud AM, Lepine F, Deziel E (2010) Rhamnolipids: diversity of structures,
3 microbial origins and roles. *Appl Microbiol Biotechnol* 86:1323-1336
4
5
6 Alhede M, Qvortrup K, Liebrechts R, Hoiby N, Givskov M, Bjarnsholt T (2012) Combination
7 of microscopic techniques reveals a comprehensive visual impression of biofilm
8 structure and composition. *FEMS Immunol Med Microbiol* 65: 335-342
9
10
11
12 Araujo JC, Téran FC, Oliveira RA, Nour EA, Montenegro MA, Campos JR, Vazoller RF
13 (2003) Comparison of hexamethyldisilazane and critical point drying treatments for SEM
14 analysis of anaerobic biofilms and granular sludge. *J Electron Microsc (Tokyo)* 52:429-
15 33
16
17
18
19
20 Arnold TM, Forrest GN, Messmer KJ (2007) Polymyxin antibiotics for gram-negative
21 infections. *American J Health-system Pharmacy* 64: 819-826
22
23
24 Banat IM, Franzetti A, Gandolfi I, Bestetti G, Martinotti MG, Fracchia L, Smyth TJ, Marchant
25 R, (2010) Microbial biosurfactants production, applications and future potential. *Appl*
26 *Microbiol Biotechnol* 87:427-444
27
28
29
30 Banat IM, Makkar RS, Cameotra SS (2000) Potential commercial applications of microbial
31 surfactants. *Appl Microbiol Biotechnol* 53:495-508
32
33
34 Benoit MR, Conant CG, Lonescu-Zanetti C, Schwartz M, Martin A. (2010) New Device for
35 High-Throughput Viability Screening of Flow Biofilms. *App Environ Microbiol* 76: 4136-
36 42
37
38
39
40 Benincasa M, Abalos A, Oliveira I, Manresa A (2004) Chemical structure, surface properties
41 and biological activities of the biosurfactant produced by *Pseudomonas aeruginosa* LBI
42 from soapstock. *Antonie Van Leeuwenhoek* 85:1-8
43
44
45
46 Bevins CL, Zasloff M (1990) Peptides from frog skin. *Annu Rev Biochem* 59:395-414
47
48
49 Boles BR, Thoendel M, Singh PK (2005) Rhamnolipids mediate detachment of
50 *Pseudomonas aeruginosa* from biofilms. *Mol Microbiol* 57:1210-1223
51
52
53 Brasseur R, Braun N, El Kirat K, Deleu M, Mingeot-Leclercq MP, Dufrene YF (2007) The
54 biologically important surfactin lipopeptide induces nanoripples in supported lipid
55 bilayers. *Langmuir* 23:9769-9772
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- Bueno J (2014) Anti-Biofilm Drug Susceptibility Testing Methods: Looking for New Strategies against Resistance Mechanism. *J Microbial Biochem Technol* S3: 004. doi: 10.4172/1948-5948.S3-004
- Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A (1999) The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. *J Clin Microbiol.* 37:1771-1776
- Chabane NY, Mlouka MB, Alexandre S, Nicol M, Marti S, Pestel-Caron M, Vila J, Jouenne T, Dé (2014) Virstatin inhibits biofilm formation and motility of *Acinetobacter baumannii*. *BMC Microbiol* 14:62
- Cochis A, Fracchia L, Martinotti MG, Rimondini L (2012) Biosurfactants prevent in vitro *Candida albicans* biofilm formation on resins and silicon materials for prosthetic devices. *Oral Surg Oral Med Oral Pathol Oral Radiol* 113:755-761
- Croda-García G, Grosso-Becerra V, Gonzalez-Valdez A, Servín-González L, Soberón-Chávez G (2011) Transcriptional regulation of *Pseudomonas aeruginosa* rhlR: role of the CRP orthologue Vfr (virulence factor regulator) and quorum-sensing regulators LasR and RhIR. *Microbiol.* 157:2545-55
- Costa SG, Deziel E, Lepine F (2011) Characterization of rhamnolipid production by *Burkholderia glumae*. *Lett Appl Microbiol* 53:620-627
- D'Auria L, Deleu M, Dufour S, Mingeot-Leclercq MP, Tyteca D (2013) Surfactins modulate the lateral organization of fluorescent membrane polar lipids: a new tool to study drug : membrane interaction and assessment of the role of cholesterol and drug acyl chain length. *Biochim Biophys Acta* 1828:2064-2073
- Davey ME, Caiazza NC, O'Toole GA (2003) Rhamnolipid surfactant production affects biofilm architecture in *Pseudomonas aeruginosa* PAO1. *J Bacteriol* 185:1027-1036
- Davies D (2003) Understanding biofilm resistance to antibacterial agents. *Nat Rev Drug Discov* 2:114-122
- Decho AW (2013) The EPS matrix as an adaptive bastion for biofilms: introduction to special issue. *Int J Mol Sci* 14:23297-23300
- Deng Y, Lu Z, Bi H, Lu F, Zhang C, Bie X (2011) Isolation and characterization of peptide antibiotics LI-F04 and polymyxin B6 produced by *Paenibacillus polymyxa* strain JSa-9. *Peptides* 32:1917-1923

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- Desai JD, Banat IM (1997) Microbial production of surfactants and their commercial potential. *Microbiol Mol Biol Rev* 61:47-64
- Ding Y, Wang W, Fan M, Tong Z, Kuang R, Jiang W, Ni L (2014) Antimicrobial and anti-biofilm effect of Bac8c on major bacteria associated with dental caries and *Streptococcus mutans* biofilms. *Peptides* 52:61-7
- Domingues MM, Inacio RG, Raimundo JM, Martins M, Castanho MA, Santos NC (2012) Biophysical characterization of polymyxin B interaction with LPS aggregates and membrane model systems. *Biopolymers* 98:338-344
- Doring G, Conway SP, Heijerman HGM, Hodson ME, Hoiby N, Smyth A, Touw DJ (2000) Antibiotic therapy against *Pseudomonas aeruginosa* in cystic fibrosis: a European consensus, *Eur Respiratory J.* 16: 749-767
- Dowd SE, Wolcott RD, Sun Y, McKeehan T, Smith E, Rhoads D (2008) Polymicrobial Nature of Chronic Diabetic Foot Ulcer Biofilm Infections Determined Using Bacterial Tag Encoded FLX Amplicon Pyrosequencing (bTEFAP). *PLoS ONE* 3:e3326
- Dubern JF, Lugtenberg BJ, Bloemberg GV (2006) The ppul-rsaL-ppuR quorum-sensing system regulates biofilm formation of *Pseudomonas putida* PCL1445 by controlling biosynthesis of the cyclic lipopeptides putisolvins I and II. *J Bacteriol* 188:2898-2906
- Dusane DH, Dam S, Nancharaiah YV, Kumar AR, Venugopalan VP, Zinjarde SS (2012) Disruption of *Yarrowia lipolytica* biofilms by rhamnolipid biosurfactant. *Aquat Biosyst* 8:17
- Dusane DH, Nancharaiah YV, Zinjarde SS, Venugopalan VP (2010) Rhamnolipid mediated disruption of marine *Bacillus pumilus* biofilms. *Colloids Surf B Biointerfaces* 81:242-248
- Dusane DH, Pawar VS, Nancharaiah YV, Venugopalan VP, Kumar AR, Zinjarde SS (2011) Anti-biofilm potential of a glycolipid surfactant produced by a tropical marine strain of *Serratia marcescens*. *Biofouling* 27:645-654
- Epstein AK, Pokroy B, Seminara A, Aizenberg J (2011) Bacterial biofilm shows persistent resistance to liquid wetting and gas penetration. *Proc Natl Acad Sci U S A* 108:995-1000
- Falagas ME, Kasiakou SK (2005) Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. *Clin Infect Dis* 40:1333-1341

- 1
2
3
4 Falagas ME, Kasiakou SK (2006) Toxicity of polymyxins: a systematic review of the
5 evidence from old and recent studies. Crit Care 10:R27
6
7
8
9
10 Fracchia L, Cavallo M, Martinotti MG, Banat IM (2012) Biosurfactants and Bioemulsifiers
11 Biomedical and Related Applications – Present Status and Future Potentials. In:
12 Biomedical Science, Engineering and Technology. pp 325-370
13
14
15
16 Gakhar L, Bartlett JA, Penterman J, Mizrachi D, Singh PK, Mallampalli RK, Ramaswamy S,
17 McCray PB (2010) PLUNC is a novel airway surfactant protein with anti-biofilm activity.
18 PLoS ONE 5:e9098
19
20
21 Ganz T, Selsted ME, Szklarek D, Harwig SS, Daher K, Bainton DF, Lehrer RI (1985)
22 Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest 76:1427-1435
23
24
25
26 Girard LP, Ceri H, Gibb AP, Olson M, Sepandj F (2010) MIC versus MBEC to determine the
27 antibiotic sensitivity of *Staphylococcus aureus* in peritoneal dialysis peritonitis. Perit Dial
28 Int 30:652-656
29
30
31
32 Gudina EJ, Rocha V, Teixeira JA, Rodrigues LR (2010) Antimicrobial and antiadhesive
33 properties of a biosurfactant isolated from *Lactobacillus paracasei* ssp. *paracasei* A20.
34 Lett Appl Microbiol 50:419-424
35
36
37
38 Haba E, Pinazo A, Jauregui O, Espuny MJ, Infante MR, Manresa A (2003) Physicochemical
39 characterization and antimicrobial properties of rhamnolipids produced by
40 *Pseudomonas aeruginosa* 47T2 NCBIM 40044. Biotechnol Bioeng 81:316-322
41
42
43
44 He J, Ledesma KR, Lam WY, Figueroa DA, Lim TP, Chow DS, Tam VH (2010) Variability of
45 polymyxin B major components in commercial formulations. Int J Antimicrob Agents
46 35:308-310
47
48
49 Irie Y, O'Toole G A, Yuk MH (2005) *Pseudomonas aeruginosa* rhamnolipids *disperse*
50 *Bordetella bronchiseptica* biofilms. FEMS Microbiol Lett 250:237-243
51
52
53
54 Janek T, Lukaszewicz M, Krasowska A (2012) Antiadhesive activity of the biosurfactant
55 pseudofactin II secreted by the Arctic bacterium *Pseudomonas fluorescens* BD5. BMC
56 Microbiol 12:24
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- Jass J, Lappin-Scott HM (1996) The efficacy of antibiotics enhanced by electrical currents against *Pseudomonas aeruginosa* biofilms. J Antimicrob Chemother 38:987-1000
- Joshi-Navare K, Prabhune A (2013) A biosurfactant sophorolipid acts in synergy with antibiotics to enhance their efficiency BioMed Res Int; 1-8
- Kim KM, Lee JY, Kim CK, Kang JS (2009) Isolation and characterization of surfactin produced by *Bacillus polyfermenticus* KJS-2 . Arch Pharm Res 32:711-715
- Kiran GS, Sabarathnam B, Selvin J (2010) Biofilm disruption potential of a glycolipid biosurfactant from marine *Brevibacterium casei*. FEMS Immunol Med Microbiol 59:432-438
- Kotulova D, Slobodnikova L (2010) Susceptibility of *Staphylococcus aureus* Biofilms to Vancomycin, Gentamicin and Rifampin. Epidemiologie Mikrobiologie Imunologie 59: 80-87
- Krasowska A (2010) Biomedical activity of biosurfactants. Postepy Hig Med Dosw) 64:310-313
- Krupovic M, Daugelavicius R, Bamford DH (2007) Polymyxin B induces lysis of marine *Pseudoalteromonads* Antimicrob Agents. Chemother 51:3908-3914
- Kuiper I, Lagendijk, EL, Pickford, R, Derrick, JP, Lamers, GEM, Thomas-Oates, JE, Lugtenberg, BJJ, Bloemberg, GV (2004) Characterization of two *Pseudomonas putida* lipopeptide biosurfactants, putisolvin I and II, which inhibit biofilm formation and break down existing biofilms. Mol Microbiol 51:97-113
- Lehtinen J, Nuutila J, Lilius, EM (2004) Green fluorescent protein-propidium iodide (GFP-PI) based assay for flow cytometric measurement of bacterial viability. Cytometry 60A: 165-172
- Leis AP, Schlicher S, Franke H, Strathmann M (2005) Optically transparent porous medium for nondestructive studies of microbial biofilm architecture and transport dynamics. Appl Environ Microbiol 71:4801-4808
- Liu L, Tan X, Jia A (2012) Relationship between bacterial quorum sensing and biofilm formation--a review. Acta microbiologica Sinica 52: 271-278.
- Lourenco A, Machado H, Brito L (2011) Biofilms of *Listeria monocytogenes* produced at 12 degrees C either in pure culture or in co-culture with *Pseudomonas aeruginosa* showed reduced susceptibility to sanitizers. J Food Sci 76: M143-148

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- Lourenco A, Coenye T, Goeres DM, Donelli G, Azevedo AS, Ceri H, Coelho FL, Flemming HC, Juhna T, Lopes SP, Oliveira R, Oliver A, Shirliff ME, Sousa AM, Stoodley P, Pereira MO, Azevedo NF (2014) Minimum information about a biofilm experiment (MIABIE): standards for reporting experiments and data on sessile microbial communities living at interfaces. *Pathogens and Disease* 70: 250-256
- Luna JM, Rufino RD, Sarubbo LA, Rodrigues LR, Teixeira JA, de Campos-Takaki GM (2011) Evaluation antimicrobial and antiadhesive properties of the biosurfactant Lunasan produced by *Candida sphaerica* UCP 0995. *Curr Microbiol* 62:1527-1534
- Mandal SM (2012) A novel hydroxyproline rich glycopeptide from pericarp of *Datura stramonium*: proficiently eradicate the biofilm of antifungals resistant *Candida albicans*. *Biopolymers* 98:332-337
- Marchant R, Banat IM (2012a) Biosurfactants: a sustainable replacement for chemical surfactants? *Biotechnol Lett* 34:1597-1605
- Marchant R, Banat IM (2012b) Microbial biosurfactants: challenges and opportunities for future exploitation. *Trends Biotechnol* 30:558-565
- McLaughlin RA, Hoogewerf AJ (2006) Interleukin-1beta-induced growth enhancement of *Staphylococcus aureus* occurs in biofilm but not planktonic cultures. *Microb Pathog* 41:67-79
- Milletli Sezgin F, Coban AY, Gunaydin M (2012) Investigation of biofilm formation in *Acinetobacter baumannii* isolates and their colistin susceptibilities in biofilm. *Int J Antimicrob Agents* 41:199
- Mireles JR, 2nd, Toguchi A, Harshey RM (2001) *Salmonella enterica* serovar *typhimurium* swarming mutants with altered biofilm-forming abilities: surfactin inhibits biofilm formation. *J Bacteriol* 183:5848-5854
- Mukherji R, Prabhune A (2014) Novel glycolipids synthesized using plant essential oils and their application in quorum sensing inhibition and as antibiofilm agents. *Scientific World Journal* 2014: 890709
- Muthusamy K, Gopalakrishnan S, Ravi TK, Sivachidambaram P (2008) Biosurfactants: Properties, commercial production and application. *Current Sci.* 94: 736-747
- Neu TR (1996) Significance of bacterial surface-active compounds in interaction of bacteria with interfaces. *Microbiological Reviews* 60: 151-166

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- O'Toole GA (2011) Microtiter dish biofilm formation assay. *J Vis Exp* Jan 30;(47). pii: 2437. doi: 10.3791/2437.
- Olson ME, Ceri H, Morck DW, Buret AG, Read RR (2002) Biofilm bacteria: formation and comparative susceptibility to antibiotics. *Can J Vet Res* 66:86-92
- Pamp SJ, Tolker-Nielsen T (2007) Multiple roles of biosurfactants in structural biofilm development by *Pseudomonas aeruginosa*. *J Bacteriol* 189:2531-2539
- Pecci Y, Rivardo F, Martinotti MG, Allegrone G (2010) LC/ESI-MS/MS characterisation of lipopeptide biosurfactants produced by the *Bacillus licheniformis* V9T14 strain. *J Mass Spectrom* 45:772-778
- Pereira MO, Machado I, Simões M, Vieira MJ (2007) Preventing biofilm formation using surfactants. *BiofilmClub*©. 167-74. <http://hdl.handle.net/1822/7534> accessed May 2014.
- Pradhan AK, Pradhan N, Mall G, Panda HT, Sukla LB, Panda PK, Mishra BK (2013) Application of lipopeptide biosurfactant isolated from a halophile: *Bacillus tequilensis* CH for inhibition of biofilm. *Appl Biochem Biotechnol* 171:1362-1375
- Price NP, Rooney AP, Swezey JL, Perry E, Cohan FM (2007) Mass spectrometric analysis of lipopeptides from *Bacillus* strains isolated from diverse geographical locations. *FEMS Microbiol Lett* 271:83-89
- Quinn GA, Maloy AP, McClean S, Carney B, Slater JW (2012) Lipopeptide biosurfactants from *Paenibacillus polymyxa* inhibit single and mixed species biofilms. *Biofouling* 28:1151-1166
- Raza W, Yang X, Wu H, Wang Y, Xu Y, Shen Q (2009) Isolation and characterisation of fusaricidin-type compound-producing strain of *Paenibacillus polymyxa* SQR-21 active against *Fusarium oxysporum* f.sp.nevium. *Eur J Plant Pathol* 125:471-483
- Read RC, Roberts P, Munro N, Rutman A, Hastie A, Shryock T, Hall R, McDonald-Gibson W, Lund V, Taylor G (1992) Effect of *Pseudomonas aeruginosa* rhamnolipids on mucociliary transport and ciliary beating. *J Appl Physiol* 72: 2271–2277
- Rivardo F, Martinotti MG, Turner RJ, Ceri H (2011) Synergistic effect of lipopeptide biosurfactant with antibiotics against *Escherichia coli* CFT073 biofilm. *Int J Antimicrob Agents* 37:324-331

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- Rivardo F, Turner RJ, Allegrone G, Ceri H, Martinotti MG (2009) Anti-adhesion activity of two biosurfactants produced by *Bacillus* spp. prevents biofilm formation of human bacterial pathogens. *Appl Microbiol Biotechnol* 83:541-553
- Rodrigues L, Banat IM, Teixeira J, Oliveira R (2006a) Biosurfactants: potential applications in medicine. *J Antimicrob Chemother* 57:609-618
- Rodrigues L, Banat IM, van der Mei HC, Teixeira JA, Oliveira R (2006b) Interference in adhesion of bacteria and yeasts isolated from explanted voice prostheses to silicone rubber by rhamnolipid biosurfactants. *J Appl Microbiol* 100:470-480
- Rodrigues L, van der Mei HC, Banat IM, Teixeira J, Oliveira R (2006c) Inhibition of microbial adhesion to silicone rubber treated with biosurfactant from *Streptococcus thermophilus* A. *FEMS Immunology and Medical Microbiology* 46, 107-112
- Rodrigues L, van der Mei HC, Teixeira J, Oliveira R (2004) Influence of biosurfactants from probiotic bacteria on formation of biofilms on voice prostheses. *Appl Environ Microbiol* 70:4408-4410
- Rodrigues L, Banat IM, Teixeira J, Oliveira R (2007) Strategies for the prevention of microbial biofilm formation on silicone rubber voice prostheses. *J Biomed Materials Res Part B- Applied Biomaterials* 81B: 358-370
- Rollet C, Gal L, Guzzo J (2009) Biofilm-detached cells, a transition from a sessile to a planktonic phenotype: a comparative study of adhesion and physiological characteristics in *Pseudomonas aeruginosa*. *FEMS Microbiol Lett* 290:135-142
- Rufino RD, Luna JM, Sarubbo LA, Rodrigues LR, Teixeira JA, Campos-Takaki GM (2011) Antimicrobial and anti-adhesive potential of a biosurfactant Rufisan produced by *Candida lipolytica* UCP 0988. *Colloids Surf B Biointerfaces* 84:1-5
- Satpute SK, Banpurkar AG, Dhakephalkar PK, Banat IM, Chopade BA (2009) Methods for investigating biosurfactants and bioemulsifiers: A review. *Critical Reviews in Biotechnol* 30: 127-144
- Samadi N, Abadian N, Ahmadkhaniha R, Amini F, Dalili D, Rastkari N, Safaripour E, Mohseni FA (2012) Structural characterization and surface activities of biogenic rhamnolipid surfactants from *Pseudomonas aeruginosa* isolate MN1 and synergistic effects against methicillin-resistant *Staphylococcus aureus*. *Folia Microbiologica* 57: 501-508

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- Sepandj F, Ceri H, Gibb A, Read R, Olson M (2004) Minimum inhibitory concentration (MIC) versus minimum biofilm eliminating concentration (MBEC) in evaluation of antibiotic sensitivity of gram-negative bacilli causing peritonitis. *Perit Dial Int* 24:65-67
- Sriram MI, Kalishwaralal K, Deepak V, Gracerosepat R, Srisakthi K, Gurunathan S (2011) Biofilm inhibition and antimicrobial action of lipopeptide biosurfactant produced by heavy metal tolerant strain *Bacillus cereus* NK1. *Colloids Surf B Biointerfaces* 85:174-181
- Stepanovic S, Cirkovic I, Ranin L, Svabic-Vlahovic M (2004) Biofilm formation by *Salmonella* spp. and *Listeria monocytogenes* on plastic surface. *Lett Appl Microbiol* 38:428-432
- Stepanovic S, Vukovic D, Hola V, Di Bonaventura G, Djukic S, Cirkovic I, Ruzicka F (2007) Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by *staphylococci* . *APMIS* 115:891-899
- Stewart CR, Muthye V, Cianciotto NP (2012) *Legionella pneumophila* Persists within Biofilms Formed by *Klebsiella pneumoniae*, *Flavobacterium* sp., and *Pseudomonas fluorescens* under Dynamic Flow Conditions *PLoS ONE* 7:e50560
- Stoodley P, Sauer K, Davies DG, Costerton JW (2002) Biofilms as complex differentiated communities. *Annu Rev Microbiol* 56:187-209
- Tahmourespour A, Salehi R, Kasra Kermanshahi R (2011) *Lactobacillus acidophilus*-Derived Biosurfactant Effect on GTFB and GTFC Expression Level in *Streptococcus mutans* Biofilm Cells. *Braz J Microbiol* 42:330-339
- Velraeds MMC, van de Belt-Gritter B, Busscher HJ, Reid G, van der Mei HC (2000) Inhibition of uropathogenic biofilm growth on silicone rubber in human urine by *lactobacilli* - a teleologic approach. *World J Urology* 18: 422-426
- Villa, F, Cappitelli, F (2013) Plant-derived bioactive compounds at sub-lethal concentrations: towards smart biocide-free antibiofilm strategies. *Phytochem Rev* 12: 245-254
- Wicken AJ, Knox KW (1980) Bacterial cell surface amphiphiles. *Biochim. Biophys. Acta* 604: 1–26. Wu ZY, Ye CS, ; Guo F, Zhang SH, Yu X (2013) Evidence for Broad-Spectrum Biofilm Inhibition by the Bacterium *Bacillus* sp Strain SW9. *Appl Environ Microbiol* 79: 1735-1738

1 Xu Z, Shao J, Li B, Yan X, Shen Q, Zhang R (2013) Contribution of Bacillomycin D in
2 *Bacillus amyloliquefaciens* SQR9 to Antifungal Activity and Biofilm Formation. Appl
3 Environ Microbiol 79: 808-815
4

5 Zakaria Gomaa E (2013) Antimicrobial and anti-adhesive properties of biosurfactant
6 produced by *lactobacilli* isolates, biofilm formation and aggregation ability. J Gen Appl
7 Microbiol. 2013;59 :425-36
8
9

10 Zhang Y (2014) Persisters, persistent infections and the Yin-Yang model. Emerg Microbes
11 Infect 3: e3. Published online: doi:10.1038/emi.2014.3
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 1 Selected biosurfactants reported in literature with antibiofilm/microbial activities.

Biosurfactant class	Name	Source	Reference	Effectiveness
Lipopeptide	Putisolvin I & II	<i>Pseudomonas putida</i>	Kuiper et al. 2004	Biofilm inhibition of <i>Pseudomonas</i> spp.
Lipopeptide	Pseudofactin II		Janek et al. 2010	Effective against <i>E. coli</i> , <i>Enterococcus faecalis</i> , <i>Proteus mirabilis</i> and <i>Candida sp.</i>
Lipopeptide	NS	<i>Bacillus subtilis</i>	Mireles et al. 2001	Biofilm inhibition of <i>S. entrica</i> on urethral catheter
Lipopeptide	Fengycin	<i>B. subtilis</i> & <i>B. licheniformis</i>	Rivardo et al. 2009	Inhibition of pathogenic <i>E. coli</i> & <i>S. entrica</i>
Lipopeptide	NS	Heavy metal tolerant strain of <i>Bacillus</i>	Sriram et al. 2011	Inhibits Gram positive and negative bacteria and fungi
Lipopeptide	NS	<i>Bacillus</i> sp. strain SW9	Wu et al. 2013	Inhibits biofilm formation in a wide range of bacteria
Lipopeptide	NS	<i>Bacillus tequilensis</i>	Pradhan et al. 2013	Biofilm inhibition of <i>E. coli</i> & <i>Streptococcus mutans</i>
Lipopeptide	L. fermentum B54	<i>Lactobacillus</i>	Velraeds et al. 2000	Inhibits uropathogens
Glycolipids	NS	<i>Brevibacterium casei.</i>	Kiran et al. 2010	Inhibits mixed pathogenic biofilm bacteria
Mixture of biosurfactants	Lunasan	<i>Candida sphaerica</i>	Luna et al. 2011	Inhibition of <i>P. aeruginosa</i> and <i>S. agalactae</i>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

NS	NS	<i>Lactobacillus paracasei</i> A20	Gudina et al. 2010	Biofilm inhibition for a range of bacteria, yeasts & filamentous fungi.
Glycolipid	Rhamnolipid	<i>P. aeruginosa</i>	Rodrigues et al. 2006b	Inhibits biofilms in <i>S. aureus</i> <i>Candida tropicalis</i>
Glycolipid	Rhamnolipid	<i>P. aeruginosa</i>	Dusane et al. 2010	Inhibits <i>B. pumilus</i>
Mixed biosurfactants		<i>Lactococcus lactis</i> / <i>Strep thermophilus</i>	Rodrigues et al. 2004	Effective against <i>Staphylococcus</i> , <i>Streptococcus</i> , <i>Rothia</i> and <i>Candida sp.</i>
NS	NS	<i>Robinia pseudocacia</i> / <i>Nerium oleander</i>	Cochis et al. 2012	Effective against <i>C. albicans</i>
Glycolipids	Rhamnolipid	<i>P. aeruginosa</i>	Dusane et al. 2012	Effective against <i>Yarrowia sp.</i>
NS	Rufisan	<i>Candida lypolytica</i>	Rufino et al. 2011	Effective against <i>Streptococcus sp</i>
Glycolipid	Glucose + palmitic acid	<i>Serratia Marsecens</i>	Dusane et al. 2011	Effective against <i>C. albicans</i> , <i>P. aeruginosa</i> and <i>B. pumilus</i>

NS= Not specified

Figures legends

Figure 1. Calgary Biofilm Device (CBD) measures the minimum biofilm eradication concentration (MBEC). (1) Biofilms cultivated on pegs in 1/10th Muller Hinton broth (2) Pegs rinsed with PBS (3) Pegs exposed to test substances in new wells (4) Pegs rinsed in PBS (5) Biofilm removed by sonicating pegs into sterile media (6) Remaining viable bacteria in wells is proportional to the biofilm biomass.

Figure 2. Biosurfactants: (A) Polymyxin B₂, (B) Fengycin-like peptide, (C) Putisolvin II and (D) Pseudofactin II:

Figure 3. Biosurfactants : (A) Surfactin, (B) - Polymyxin D1, (C) Fusaricidin B1, (D) Rhamnolipids: mono rhamnolipid, (l-rhamnosyl- β -hydroxydecanoyl- β -hydroxydecanoate)(RL-1) and (E) di-rhamnolipid, (l-rhamnosyl l-rhamnosyl- β -hydroxydecanoyl- β -hydroxydecanoate (RL-2), DAB = diaminobutyric acid.

Figure 4. Representative images depicting the effect of rhamnolipids on pre-formed biofilms of *P. aeruginosa* PAO1 on cover slips. Cells were stained with crystal violet 1%, and observed using a phase contrast microscope at 40x. (A) *P. aeruginosa* PAO1 Biofilms after 48h. (B) After 30min treatment with rhamnolipids (5%) v/v on 48h biofilms.

Figure 5. Biofilm formation by *Bacillus subtilis* BBK006 on coverslips. Cells were stained with Syto9®, and observed using a fluorescence microscope at 40x. The bar represent 100 μ m . (A) *Bacillus subtilis* BBK006 biofilms after 48h as a control. (B) After 30min treatment in the presence of Sophorolipids 5% v/v on 48h preformed biofilms.

Figure 1



Biofilms cultivated in wells with pegs



Biofilms mature



Non-adherent bacteria rinsed off



Biofilms incubated with test substance




Rinse off inhibitor



Sonicate pegs into media growth = biofilm survival

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65


Figure 2




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 3


A




B




C



D



E



1
2
3
4
5 **Figure 4**
6
7
8
9
10
11





Figure 5

